Perth, Australia (ABN Newswire) - MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") is pleased to attach a copy of a news release by MediPharm Labs Inc ("MediPharm Labs") (CVE:LABS) announcing that it has entered into a 3-year cannabis concentrate program agreement with Supreme Cannabis Company Inc ("Supreme Cannabis") (CVE:FIRE).
MMJ owns 5.2 million shares and 2.9 million warrants (exercisable at CAD$1.20 per share by October 2020) in MediPharm Labs.
To view the news release, please visit:
http://abnnewswire.net/lnk/873PJPU0
MMJ owns 5.2 million shares and 2.9 million warrants (exercisable at CAD$1.20 per share by October 2020) in MediPharm Labs.
To view the news release, please visit:
http://abnnewswire.net/lnk/873PJPU0
About MMJ PhytoTech Ltd:
MMJ PhytoTech Limited (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/
Source:
MMJ PhytoTech Ltd
Contact:
Investor and Media Enquiries: Jason Conroy Chief Executive Officer T: +61-2-8098-0819 E: info@mmjgh.com.au